NovaBridge Biosciences (NBP) H.C. Wainwright “HCW@Home” series summary

Company transformation and strategic focus

• Underwent significant transformation, divested China operations, and now operates with a lean U.S.-based team focused on capital efficiency and clinical pipeline advancement.

• Pipeline centers on three clinical-stage assets, with primary focus on Claudin 18.2 4-1BB bispecific (Giva) for frontline gastric cancer.

• Strong financial position with $168 million on balance sheet as of Q1, supporting key clinical readouts over the next 6–12 months.

Clinical data and differentiation

• Giva shows 18% ORR as monotherapy in heavily pretreated gastric cancer, with favorable safety profile.

• Combination with standard nivo chemo in 17-patient study shows promising ORR and safety, with no additional toxicity observed.

• Giva targets a broad range of Claudin 18.2 expressors, with activity seen even at low expression levels.

• Differentiated by conditional 4-1BB activation, minimizing off-tumor toxicity and avoiding ADCC/CDC-related adverse events.

• Grade 3+ adverse events lower than competing ADCs and T-cell engagers, supporting suitability for frontline use.

Market opportunity and expansion plans

• Addressable market for frontline Claudin 18.2-positive gastric cancer estimated at $12 billion across U.S., EU, and Japan.

• Focused on establishing Giva as a bolt-on to standard of care in frontline metastatic gastric cancer.

• Exploring future expansion into locally advanced gastric, pancreatic, and biliary tract cancers, leveraging high Claudin 18.2 expression.

• Considering combinations with other targeted therapies (e.g., FGFR2 antibodies) and potential for broader tumor agnostic indications.